; and (B) data through public health surveillance systems, surveys, questionnaires, and databases of health care records, including, as appropriate, the Behavioral Risk Factor Surveillance System, the Youth Risk Behavioral Surveillance System, the Monitoring the Future health survey, the National Survey on Drug Use and Health, or the Healthcare Cost and Utilization Project (or any successor surveys). (2) Privacy Any data collected under paragraph (1) shall be collected in manner that protects personal privacy to the extent, at a minimum, that is required under applicable Federal and State law. . 3. Rescheduling of marihuana (a) In general Subsection (c) of schedule I of section 202(c) of the Controlled Substances Act ( 21 U.S.C. 812(c) ) is amended by striking paragraph (10). (b) Schedule III Schedule III of section 202(c) of the Controlled Substances Act ( 21 U.S.C. 812(c) ) is amended by adding at the end the following: (f) Marihuana. . 4. Centers of excellence in cannabis research (a) In general Part B of title IV of the Public Health Service Act ( 42 U.S.C. 284 et seq.), as amended by section 2(a), is further amended by adding at the end the following: 409L. Centers of excellence in cannabis research (a) Designation (1) In general The Director of NIH shall designate institutions of higher education as Centers of Excellence in Cannabis Research for the purpose of interdisciplinary research related to cannabis and other biomedical, behavioral, and social issues related to cannabis. No institution of higher education may be designated as a Center unless an application therefor has been submitted to, and approved by, the Director of NIH. Such an application shall be submitted in such manner and contain such information as the Director of NIH may reasonably require. The Director of NIH may not approve such an application unless— (A) the application contains or is supported by reasonable assurances that— (i) at least 1 individual employed by the applicant— (I) is registered under section 303(f) of the Controlled